Role of farnesyltransferase inhibitors in hematologic malignancies

Edgardo S. Santos, Joseph D Rosenblatt, Mark Goodman

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The treatment of hematologic malignancies has progressed in the last few years. Identification of new pathways and target molecules in leukemia has ushered in a promising new era of therapy. Ras mutations have recently been implicated in the pathogenesis of acute leukemia, and inhibition of Ras signaling through the use of farnesyltransferase inhibitors (FTIs) has shown promise in early trials in acute myeloid leukemia (AML). Responses have not correlated with the presence of Ras mutations, suggesting that novel pathways are involved. In several early trials, FTIs have shown activity as single agents in poor-risk AML, suggesting a potential role in combination with standard chemotherapy. FTIs are now being tested in other clinical settings, such as myelodysplasia, chronic myelogenous leukemia and multiple myeloma, with encouraging preliminary activity.

Original languageEnglish
Pages (from-to)843-856
Number of pages14
JournalExpert Review of Anticancer Therapy
Volume4
Issue number5
StatePublished - Oct 1 2004

Fingerprint

Farnesyltranstransferase
Hematologic Neoplasms
Acute Myeloid Leukemia
Leukemia
Mutation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Multiple Myeloma
Drug Therapy
Therapeutics

Keywords

  • BMS-214662
  • Farnesyltransferase inhibitor
  • Lonafarnib
  • Mitogen-activated protein kinase
  • Myelodysplasia
  • Myelofibrosis
  • Myeloid leukemia
  • Ras mutation
  • RhoB protein
  • Tipifarnib

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research

Cite this

Role of farnesyltransferase inhibitors in hematologic malignancies. / Santos, Edgardo S.; Rosenblatt, Joseph D; Goodman, Mark.

In: Expert Review of Anticancer Therapy, Vol. 4, No. 5, 01.10.2004, p. 843-856.

Research output: Contribution to journalArticle

@article{67dfe24de3c84b309cc9eb55deeb4efa,
title = "Role of farnesyltransferase inhibitors in hematologic malignancies",
abstract = "The treatment of hematologic malignancies has progressed in the last few years. Identification of new pathways and target molecules in leukemia has ushered in a promising new era of therapy. Ras mutations have recently been implicated in the pathogenesis of acute leukemia, and inhibition of Ras signaling through the use of farnesyltransferase inhibitors (FTIs) has shown promise in early trials in acute myeloid leukemia (AML). Responses have not correlated with the presence of Ras mutations, suggesting that novel pathways are involved. In several early trials, FTIs have shown activity as single agents in poor-risk AML, suggesting a potential role in combination with standard chemotherapy. FTIs are now being tested in other clinical settings, such as myelodysplasia, chronic myelogenous leukemia and multiple myeloma, with encouraging preliminary activity.",
keywords = "BMS-214662, Farnesyltransferase inhibitor, Lonafarnib, Mitogen-activated protein kinase, Myelodysplasia, Myelofibrosis, Myeloid leukemia, Ras mutation, RhoB protein, Tipifarnib",
author = "Santos, {Edgardo S.} and Rosenblatt, {Joseph D} and Mark Goodman",
year = "2004",
month = "10",
day = "1",
language = "English",
volume = "4",
pages = "843--856",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Role of farnesyltransferase inhibitors in hematologic malignancies

AU - Santos, Edgardo S.

AU - Rosenblatt, Joseph D

AU - Goodman, Mark

PY - 2004/10/1

Y1 - 2004/10/1

N2 - The treatment of hematologic malignancies has progressed in the last few years. Identification of new pathways and target molecules in leukemia has ushered in a promising new era of therapy. Ras mutations have recently been implicated in the pathogenesis of acute leukemia, and inhibition of Ras signaling through the use of farnesyltransferase inhibitors (FTIs) has shown promise in early trials in acute myeloid leukemia (AML). Responses have not correlated with the presence of Ras mutations, suggesting that novel pathways are involved. In several early trials, FTIs have shown activity as single agents in poor-risk AML, suggesting a potential role in combination with standard chemotherapy. FTIs are now being tested in other clinical settings, such as myelodysplasia, chronic myelogenous leukemia and multiple myeloma, with encouraging preliminary activity.

AB - The treatment of hematologic malignancies has progressed in the last few years. Identification of new pathways and target molecules in leukemia has ushered in a promising new era of therapy. Ras mutations have recently been implicated in the pathogenesis of acute leukemia, and inhibition of Ras signaling through the use of farnesyltransferase inhibitors (FTIs) has shown promise in early trials in acute myeloid leukemia (AML). Responses have not correlated with the presence of Ras mutations, suggesting that novel pathways are involved. In several early trials, FTIs have shown activity as single agents in poor-risk AML, suggesting a potential role in combination with standard chemotherapy. FTIs are now being tested in other clinical settings, such as myelodysplasia, chronic myelogenous leukemia and multiple myeloma, with encouraging preliminary activity.

KW - BMS-214662

KW - Farnesyltransferase inhibitor

KW - Lonafarnib

KW - Mitogen-activated protein kinase

KW - Myelodysplasia

KW - Myelofibrosis

KW - Myeloid leukemia

KW - Ras mutation

KW - RhoB protein

KW - Tipifarnib

UR - http://www.scopus.com/inward/record.url?scp=5444251026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5444251026&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 843

EP - 856

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 5

ER -